Quality: A Potential Strategic Roadmap for Professional Organizations Ready to Lead | Part 3 of 3
The Strategic Alignment of Professional Organizations with Payer Value Frameworks
Over the past two posts (Part 1 and Part 2), I've argued that our national quality measurement infrastructure is structurally broken, 1) built on fragmented governance, claims-based data, and marginal incentives and, 2) that FHIR-based interoperability now makes a fundamentally better approach possible.
This final post is about what professional organizations should actually do about it.
The stakes are real. Professional societies that lead this transition will define how quality is measured and rewarded in their specialties for the next generation. Those that wait will find their clinical standards continue to be interpreted, approximated, and occasionally misrepresented by payers and measurement bodies operating without their input.
Integrate Economic Value Into Guidelines … Systematically
The most powerful thing a professional organization can do to align with payer value frameworks is to speak in the language payers actually use....cost-effectiveness.
This doesn't mean subordinating clinical judgment to economic metrics. It means acknowledging that health systems and payers are making allocation decisions whether or not clinical guidelines inform them, and that specialty societies with the deepest clinical evidence base are uniquely positioned to provide that guidance credibly.
The model for this exists and it's already in practice for some. The ACC/AHA 2025 Guideline Methodology Manual (see page 9) explicitly incorporates cost and value analysis as a formal component of clinical practice guideline development. Cost-effectiveness is not an afterthought layered onto finished recommendations, and instead it is embedded in the methodology from the outset, with standardized thresholds, structured value classifications, and a framework for rating the certainty of economic evidence alongside clinical evidence. That is a meaningful structural commitment, and it sets a bar that other specialty societies should study and build toward.
The American College of Physicians has taken a complementary approach on the measurement side. ACP has been publicly vocal about the need to focus quality measurement on a smaller number of high-impact, evidence-grounded conditions — arguing that not everything that can be measured should be, and that the current proliferation of metrics imposes real costs without proportional clinical benefit. Their call for a unified national focus on the most important and common clinical conditions is exactly the kind of institutional position that can shift the conversation at the federal and payer level.
What it requires is methodological commitment to treat economic evidence with the same systematic rigor as clinical evidence, establishing reference standards for future analyses, and being willing to produce transparent value classifications even when the results are inconvenient. This also aligns with CMS approaches around HEOR evidence required of the industry to attain new billing codes (e.g., HCPCS, CPT, etc.)
Develop FHIR-Based Quality Measure Specifications
This is where the technical opportunity of Part 2 becomes organizational strategy.
Professional organizations should move toward developing FHIR implementation guides for their specialty to define the data elements required for accurate population identification, authoring measure logic in Clinical Quality Language (CQL) that can be executed directly against FHIR repositories and creating payer-ready documentation that eliminates the interpretation gap.
The CodeX oncology model is instructive where ASCO and ASTRO partnered with technical stakeholders to produce executable quality specifications that payers could adopt without translation. The result was more accurate measurement, less administrative burden, and clinical organizations maintaining control over how their specialty's quality was defined and assessed.
This is not work that most specialty societies have traditionally done. It requires informatics capacity, technical partnership, and a willingness to engage deeply with implementation rather than simply publishing specifications and stepping back. But it is the work that actually closes the translation gap and the organizations willing to do it will hold enormous influence over how clinical quality is operationalized in payer contracts and federal value-based programs.
Couple Economic Value With Recommendation Strength
One of the most transformative moves available to professional organizations is to link economic value directly to recommendation classification so that the strength of a clinical recommendation reflects not just clinical evidence but cost-effectiveness evidence as well. This also creates research anchor points where known-unknowns are cleanly evaluated and are set up for active research and validation.
This creates something the current system almost entirely lacks - market incentives embedded in guideline structure. When a Class I recommendation requires both strong clinical evidence and cost-effectiveness at an accepted threshold, it changes what manufacturers, health systems, and payers do. Manufacturers have incentives to price interventions in alignment with the value they generate. Payers have a credible, clinically grounded basis for coverage decisions. Clinicians have guidance that integrates both the science of benefit and the reality of resource allocation.
This is transformational, not incremental. It moves professional organizations from publishing guidelines that payers interpret inconsistently, to shaping the economic architecture of care delivery in their specialty.
Focus on the Vital Few
One of the clearest lessons from two decades of quality measurement failure is that proliferation is not a strategy. Analysis of AHRQ's quality indicators found that seven of them account for 93% of measurable population health benefit. Yet measurement programs have continued to expand, imposing burden without proportional value.
Professional organizations should resist the temptation to be comprehensive. The goal is not to measure everything, but rather to measure what matters, measure it accurately, and create incentives that drive meaningful change.
This means actively retiring low-value process measures that do not link to improved outcomes. It means concentrating development resources on the vital few measures with demonstrated population health impact. It means preferring outcome measures over process proxies. And it means being willing to say (publicly and credibly) that measuring certain things is not worth the administrative cost of doing so.
Build Toward Equity From The Start
Value-based payment has enormous potential as a lever for addressing health equity and as a mechanism that inadvertently entrenches disparities, if equity isn't built into program design from the outset.
Professional organizations should embed health equity considerations into both guideline development and quality measure design: incorporating differential effectiveness across populations into cost-effectiveness frameworks, structuring data elements to enable equity analysis, adjusting for social determinants of health in risk models, and including patient priorities beyond just clinical endpoints to define what quality means.
This is both the right thing and the strategically smart thing. Payers and CMS are increasingly focused on health equity as a dimension of quality. Professional societies that develop credible, clinically grounded equity frameworks will find receptive audiences in exactly the policy and payer stakeholders they need to influence.
Engage Payers as Technical Partners
The old model of professional organization-payer interaction is largely adversarial or transactional where societies publish guidelines, payers develop coverage policies, gaps emerge, where utilization management and appeals processes fill in the cracks. The new model must be different.
FHIR-based quality measurement only succeeds if payers can implement it. That requires professional organizations to do something unfamiliar…..sit with payers in technical implementation conversations, pilot clinical data-based quality calculation in real contracting environments and create feedback loops between implementation experience and specification refinement.
This is not about giving payers control over clinical standards. It's about ensuring that the specifications professional organizations develop are actually implementable and that when implementation barriers emerge (and they will), they get resolved through clinical input rather than administrative approximation.
A Three-Phase Strategic Roadmap
Phase 1 — Foundation (Years 1–2): Establish quality measurement infrastructure grounded in clinical data, not claims. Critically assess existing measure portfolios and retire low-value indicators. Begin FHIR profile development by mapping specialty-specific clinical data elements to FHIR resources leveraging and stewarding Value-Set Authority Center (VSAC) frameworks. Establish connections with TEFCA-qualified health information networks.
Phase 2 — Integration (Years 2–4): Incorporate cost-effectiveness systematically into guideline development. Author FHIR-based quality measures using CQL. Pilot clinical data-based quality calculation with early-adopter payers. Develop payer-ready implementation guides. Generate economic evidence for priority clinical areas.
Phase 3 — Transformation (Years 4–5+): Couple economic value with recommendation strength across the guideline portfolio. Scale FHIR-based measurement across payer contracts. Advocate for CMS adoption of FHIR-based measures in federal value-based programs. Establish continuous improvement feedback loops between clinical data, quality measurement, and guideline updates.
What's Actually At Stake
The quality measurement system did not fail because of bad intentions. It failed because of structural misalignment including measurement authority held by bodies without clinical ownership, data systems inadequate to the specifications being enforced, and incentives too small to drive meaningful change.
Professional organizations have the clinical authority, the registry infrastructure, the guideline ownership, and the stakeholder trust to build something fundamentally different. They have every incentive to do so because the alternative is continued delegation of clinical quality definition to organizations and data sources that cannot represent what the specialty actually knows about what constitutes good care.
The paradigm shift is clear enough shifting from professional organizations developing quality metrics that payers interpret using claims data, to professional organizations developing FHIR-based quality measure specifications that payers implement directly using clinical data. The technology is ready. The regulatory environment is aligning. The infrastructure is being built.
The only question is which professional organizations will lead…. and which will be led.
----------------------------------------------------------------
A note on who's doing this work: Kiser Healthcare Solutions (KHS) is actively operating at the crossroads of digital quality, professional organizations, and value-based care helping professional organizations, payers and providers advance quality without adding administrative burden or questionable ROI. Their focus on FHIR interoperability and data-driven strategy reflects exactly the kind of implementation partner professional organizations need as they make this transition. Worth knowing about: kisersolutions.com
Special thanks to Kristyne Reoger and Jennifer Bitterman for their contributions to this piece.
----------------------------------------------------------------
This is the final installment of a three-part series on professional organizations and payer value alignment. Part 1 examined the structural failures of the current quality measurement system. Part 2 explored the translation gap between clinical guidelines and payer actuaries, and the emerging FHIR/TEFCA infrastructure that makes a different approach possible.